Demographics of 591 patients who received protamine during cardiopulmonary bypass surgery
| Patient characteristics . | Total no. of patients: 591 (100%) . | Status of protamine-heparin IgG-antibodies at baseline . | P value . | ||
|---|---|---|---|---|---|
| No antibodies (n = 534; 90.4%) . | Non–platelet-activating antibodies (n = 50; 8.4%) . | Platelet-activating antibodies (n = 7; 1.2%) . | |||
| Age (y) | 67.5 ± 9.5 | 67.5 ± 9.7 | 67.6 ± 7.6 | 72.3 ± 8.7 | .414 |
| Female sex (%) | 162 (27.4) | 145 (27.2) | 16 (32.0) | 1 (14.3) | .688 |
| Body mass index | 29.0 ± 4.6 | 28.9 ± 4.6 | 30.3 ± 4.3 | 28.9 ± 4.1 | .281 |
| Diabetes (%) | 233 (39.4) | 195 (36.5) | 31 (62.0) | 7 (100) | < .001 |
| Hypertension (%) | 539 (91.2) | 483 (90.4) | 50 (100.0) | 6 (85.7) | .221 |
| Previous myocardial infarction (%) | 70 (11.8) | 66 (12.4) | 3 (6.0) | 1 (14.3) | .346 |
| Congestive heart failure (%) | 5 (0.8) | 2 (0.4) | 3 (6.0) | 0 (0) | .001 |
| Peripheral vascular disease (%) | 102 (17.3) | 93 (17.4) | 7 (14.0) | 2 (28.6) | .635 |
| Patient characteristics . | Total no. of patients: 591 (100%) . | Status of protamine-heparin IgG-antibodies at baseline . | P value . | ||
|---|---|---|---|---|---|
| No antibodies (n = 534; 90.4%) . | Non–platelet-activating antibodies (n = 50; 8.4%) . | Platelet-activating antibodies (n = 7; 1.2%) . | |||
| Age (y) | 67.5 ± 9.5 | 67.5 ± 9.7 | 67.6 ± 7.6 | 72.3 ± 8.7 | .414 |
| Female sex (%) | 162 (27.4) | 145 (27.2) | 16 (32.0) | 1 (14.3) | .688 |
| Body mass index | 29.0 ± 4.6 | 28.9 ± 4.6 | 30.3 ± 4.3 | 28.9 ± 4.1 | .281 |
| Diabetes (%) | 233 (39.4) | 195 (36.5) | 31 (62.0) | 7 (100) | < .001 |
| Hypertension (%) | 539 (91.2) | 483 (90.4) | 50 (100.0) | 6 (85.7) | .221 |
| Previous myocardial infarction (%) | 70 (11.8) | 66 (12.4) | 3 (6.0) | 1 (14.3) | .346 |
| Congestive heart failure (%) | 5 (0.8) | 2 (0.4) | 3 (6.0) | 0 (0) | .001 |
| Peripheral vascular disease (%) | 102 (17.3) | 93 (17.4) | 7 (14.0) | 2 (28.6) | .635 |